NeuroPace Inc NPCE
Nasdaq · XNAS · stock · Surgical & Medical Instruments & Apparatus
Chart by TradingView
5/9
Piotroski F — financial health
-13.13
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $100.0M | -$21.5M | $77.2M | -$11.3M | $19.0M |
| 2024 | $79.9M | -$27.1M | $59.1M | -$18.3M | $8.0M |
| 2023 | $65.4M | -$33.0M | $48.1M | -$19.9M | $20.7M |
| 2022 | $45.5M | -$47.1M | $32.5M | -$37.5M | $34.8M |
| 2021 | $45.2M | -$36.1M | $33.4M | -$25.0M | $73.5M |
| 2020 | $41.1M | -$24.3M | $30.3M | -$21.7M | -$147.8M |
Why these scores methodology →
Piotroski F-score: 5/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -13.13 (distress)
- Working capital / assets 0.722
- Retained earnings / assets -5.233
- EBIT / assets -0.155
- Equity / liabilities 0.22
Source: SEC EDGAR filings · CIK 0001528287 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.